RxDoctor Payments Data

Katheryn Mullin

Nurse Practitioner · Elyria, OHNPI 1558663989

Payments from drug & device makers

$1,120in general payments, 2019–2025

Across 39 payments — averaging $28.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$248
  • Lilly USA, LLC$174
  • Medtronic$157
  • GSK$140
  • Abbott$106
  • Biohaven Pharmaceuticals, Inc.$85
  • plus $211 from 6 others

What the payments were for

  • Food & beverage$1,07796%
  • Education$434%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,120 in reported general payments places this provider in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$12,182
Medicare patients
107
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$46,624
JardianceEmpagliflozin14$21,132
JanuviaSitagliptin Phosphate12$17,076
MounjaroTirzepatide12$16,231
XareltoRivaroxaban11$15,790
Atorvastatin Calcium203$2,078
Esomeprazole Magnesium17$1,294
Metoprolol Succinate60$1,039
Celecoxib17$974
Albuterol Sulfate HfaAlbuterol Sulfate36$958
Metformin Hcl ErMetformin Hcl76$784
FenofibrateFenofibrate Nanocrystallized15$756
Levothyroxine Sodium68$755
Rosuvastatin Calcium48$725
Lisinopril131$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$46,62433 claims
MerckJanuvia$29$17,07612 claims
Lilly USA, LLCMounjaro$174$16,23112 claims
AbbVieSynthroid$248$45312 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$14$20814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Elyria

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →